新股消息 | 征祥医药递表港交所

Group 1 - The core viewpoint of the article is that Zhengxiang Pharmaceutical (Nanjing) Group Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CICC as its sole sponsor [1] - Zhengxiang Pharmaceutical is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies to address unmet medical needs in the fields of viral infectious diseases, oncology, and inflammatory diseases [1] Group 2 - Zhengxiang Pharmaceutical's core product, Marcilosavir tablets, is an inhibitor targeting the influenza virus polymerase acidic protein (PA) endonuclease, which received New Drug Application (NDA) approval from the National Medical Products Administration (NMPA) for the treatment of adult influenza in July 2025 [4] - The company is expanding the indications of Marcilosavir to include adolescent patients and post-exposure prophylaxis [4] - Zhengxiang Pharmaceutical has developed a pipeline of six drug assets, including the commercialized Marcilosavir tablets, a clinical-stage Marcilosavir suspension for pediatric influenza patients, and ZX-8177 for solid tumors in phase I clinical trials, along with ZX-12042B for human papillomavirus (HPV) infection currently in IND application stage [4] - Additionally, the company has two preclinical candidates targeting herpes simplex virus (HSV) infections and autoimmune diseases [4]